Author

C. Sedlik

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Organism:mouse· 3 Research Focus:host-pathogen & immune response· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

e. piaggio· 3 shared J. Denizeau· 2 shared W. Richer· 2 shared A. Bochnakian· 1 shared A. del Castillo· 1 shared A. Gruppi· 1 shared a. mencattini· 1 shared A. Nicolas· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

e. piaggio

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Ex vivo quantification of anti-tumor T-cell activity upon anti-PD-1 treatment in patient-derived lung tumor-on-chip

i. veith, a. mencattini, m. nurmik, i. damei, c. lansche, s. brosseau, g. gropplero, s. corgnac, j. filippi, n. pote, p. mordant, j. tosello, c. sedlik, e. piaggio, n. girard, , M. C. PARRINI

This study develops and validates lung-tumor-on-chip platforms to measure ex vivo anti-PD-1 treatment effects on T-cell activity using live imaging and image analysis.

bioRxiv · Jun 21, 2023 · PreprintCancer Biology

CD39+ conventional CD4+ T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade

S. N. Bossio, C. Abrate, J. Tosello Boari, C. Rodriguez, F. Canale, M. C. Ramello, W. Richer, D. Rocha, C. Sedlik, A. Salomon, E. Borcoman, A. del Castillo, A. Gruppi, E. Fernandez, E. V. Acosta Rodriguez, C. L. Montes

The paper identifies CD39+ CD4+ T cells in tumors with exhaustion and cytotoxic traits, showing their expansion with CTLA-4 blockade and association with better survival in breast cancer.

bioRxiv · Jan 30, 2023Immunology

Cellular selectivity of STING stimulation determines priming of tumor-specific T cell responses

B. Jneid, A. Bochnakian, F. Delisle, E. Djacoto, J. Denizeau, C. Sedlik, F. Fiore, R. Kramer, I. Walters, S. Carlioz, B. Malissen, E. Piaggio, N. Manel

This study shows that targeting STING in dendritic cells with cGAMP-VLP enhances tumor-specific T cell responses and synergizes with PD1 blockade for tumor eradication, while synthetic CDN causes systemic T cell activation without specific T cell differentiation.

bioRxiv · Dec 1, 2021Immunology

Tissue-resident FOLR2+ macrophages associate with tumor-infiltrating CD8+ T cells and with increased survival of breast cancer patients.

R. N. Ramos, Y. Missolo-Koussou, Y. Gerber-Ferder, C. Bromley, M. Bugatti, N. G. Nunez, J. Boari Tosello, W. Richer, J. Denizeau, C. Sedlik, P. Caudana, F. Kotsias, L. L. Niborski, S. Viel, M. Bohec, , J. Helft

The paper identifies FOLR2+ macrophages in breast cancer that correlate with improved patient survival and co-localize with CD8+ T cells across multiple cancers.

bioRxiv · Apr 12, 2021 · PreprintImmunology